Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
7 studies found for:    extracorporeal + photopheresis AND graft | Open Studies
Show Display Options
Rank Status Study
1 Recruiting A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-Disease
Condition: Chronic Graft-versus-host-disease
Interventions: Procedure: Extracorporeal Photopheresis (ECP);   Drug: Interleukin-2
2 Recruiting Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)
Condition: Refractory Chronic Graft Versus Host Disease (cGVHD)
Intervention: Device: Photopheresis Theraflex ECP™
3 Not yet recruiting Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease
Conditions: Cutaneous T-Cell Lymphoma, Unspecified;   Chronic Graft Versus Host Disease in Skin
Intervention: Drug: ECP with 5-aminolevulinic acid
4 Recruiting Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis
Condition: Graft Versus Host Disease (GVHD)
Interventions: Procedure: extracorporeal photopheresis;   Other: laboratory biomarker analysis
5 Recruiting Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease
Condition: Chronic Graft Versus Host Disease
Interventions: Biological: Aldesleukin;   Procedure: Extracorporeal Photopheresis;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
6 Recruiting Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)
Condition: Graft Versus Host Disease
Interventions: Other: medical chart review;   Other: quality-of-life assessment
7 Not yet recruiting A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Condition: Graft-versus-host Disease
Interventions: Drug: Ruxolitinib;   Drug: Extracorporeal photopheresis (ECP);   Drug: Low-dose methotrexate (MTX);   Drug: Mycophenolate mofetil (MMF);   Drug: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus);   Drug: Infliximab;   Drug: Rituximab;   Drug: Pentostatin;   Drug: Imatinib

Study has passed its completion date and status has not been verified in more than two years.